DOCSLIB.ORG

Directed Evolution of Bacillus Gibsonii Alkaline Protease Towards Washing Applications: a Study of Protein Adaptation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Directed Evolution of Bacillus Gibsonii Alkaline Protease Towards Washing Applications: a Study of Protein Adaptation Directed Evolution of Bacillus gibsonii Alkaline Protease towards Washing Applications: a Study of Protein Adaptation by Ronny Ernesto Martínez Moya A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biochemical Engineering Approved, Thesis Committee Prof. Dr. Ulrich Schwaneberg, RWTH Aachen University Prof. Dr. Danilo Roccatano, Jacobs University Bremen Prof. Dr. Karl-Heiz Maurer, Henkel AG & Co KGaA Date of Defense: September 10, 2010 School of Engineering and Science Table of contents Table of contents Table of contents ............................................................................................................................... i Acknowledgments........................................................................................................................... iii Abstract ........................................................................................................................................... iv Abbreviations .................................................................................................................................. vi Part I: General introduction.............................................................................................................. 1 1. Protein engineering and Directed Evolution ............................................................................ 1 2. Cold adaptation and thermal stability of enzymes ................................................................... 5 2.1. - Thermostable enzymes ................................................................................................... 6 2.1. - Cold-adapted enzymes.................................................................................................... 7 3. - Aim of the project.................................................................................................................. 9 Part II: Directed Evolution of Bacillus gibsonii Alkaline Protease towards washing applications 11 1. – Introduction ............................................................................................................................. 11 1.1. - Aim of this work ............................................................................................................... 11 1.2. –Proteases............................................................................................................................ 11 1.2.1. – Serine proteases and subtilisins................................................................................. 13 1.2.2. –Subtilisin proteases applications in industry.............................................................. 16 1.2.3. – Protein engineering in subtilisin proteases................................................................ 18 1.2.4. – B. gibsonii Alkaline Protease (BgAP)....................................................................... 21 1.3. - SeSaM............................................................................................................................... 23 1.3.1. – SeSaM principle........................................................................................................ 23 1.3.2. - SeSaM Features ......................................................................................................... 24 2. - Materials and methods ............................................................................................................. 26 2.1. – Materials........................................................................................................................... 26 2.1.1. – Chemicals.................................................................................................................. 26 2.1.2. – Bacterial strains......................................................................................................... 26 2.1.3. – Plasmids .................................................................................................................... 26 2.1.4. – Oligonucleotides ....................................................................................................... 26 2.1.5. – Cell culture media and cultivation ............................................................................ 28 2.2. - Methods ............................................................................................................................ 28 2.2.1. - Cloning ...................................................................................................................... 28 2.2.2. - Random mutagenesis library generation.................................................................... 28 2.2.3. - Protein expression...................................................................................................... 29 2.2.4. - Screening for improved activity at 15°C ................................................................... 29 2.2.5. - Screening for improved thermostability .................................................................... 30 2.2.6. - Site-directed mutagenesis and site saturation mutagenesis of BgAP variants........... 30 2.2.7. - Protein purification .................................................................................................... 30 2.2.8. - Proteolytic activity: Suc-AAPF-pNA ........................................................................ 31 2.2.8. - Enzyme activity: Azocasein....................................................................................... 31 2.2.9. - Temperature dependence of the specific activity ...................................................... 32 2.2.10. - Thermal inactivation................................................................................................ 32 2.2.11. - Thermal shift assay.................................................................................................. 32 2.2.12. - Homology modeling ................................................................................................ 33 3. – Results ..................................................................................................................................... 34 3.1. – Directed Evolution to improve activity at low temperatures ........................................... 34 3.1.1. - BgAP expression system ........................................................................................... 34 3.1.2. - Skim milk microtiter plate assay ............................................................................... 35 3.1.3. - SeSaM library generation .......................................................................................... 36 3.1.4. - Screening of BgAP SeSaM library round 1............................................................... 37 3.1.5. - Screening of BgAP SeSaM library round 2............................................................... 40 3.1.6. - Screening of BgAP SeSaM library round 3............................................................... 43 i Table of contents 3.1.8. - Purification and characterization of selected clones from Directed Evolution.......... 47 3.1.9. – Characterization using the suc-AAPF-pNA substrate............................................... 50 3.1.10. – Characterization using the macromolecular substrate Azo-casein.......................... 51 3.2. - Directed Evolution of BgAP for improved thermostability.............................................. 52 3.2.1. – Re-screening of SeSaM libraries............................................................................... 55 3.2.2. – Site-directed mutagenesis to generate variant 39IC1+N253D.................................. 57 3.2.3. - Site-directed mutagenesis and combination of amino acid substitutions .................. 58 3.2.4. - Purification and characterization of variants with improved thermostability............ 59 3.3. - Homology modeling of BgAP. ......................................................................................... 65 4. - Discussion and conclusions ..................................................................................................... 66 4.1.- Analysis of the mutations generated by SeSaM ................................................................ 66 4.2. - Directed Evolution of BgAP............................................................................................. 68 4.2.1. – Cold adaptation of BgAP .......................................................................................... 68 4.3.2. – Increasing thermal stability of BgAP........................................................................ 71 4.3. - Conclusions of Part I......................................................................................................... 75 Part III: Temperature Effects on Dynamics of Psychrophilic Protease S41 and its Thermostable Mutants in Solution. ....................................................................................................................... 76 1. – Introduction ............................................................................................................................. 76 1.1. - Aim of this work ............................................................................................................... 76 1.2. – Molecular dynamics simulations...................................................................................... 76 1.3. – Extremophiles and protein adaptation.............................................................................. 77 1.4.
Load more

Recommended publications
  • Substrate Specificities of Outer Membrane Proteases of the Omptin Family in Escherichia Coli, Salmonella Enterica, and Citrobacter Rodentium
    Substrate specificities of outer membrane proteases of the omptin family in Escherichia coli, Salmonella enterica, and Citrobacter rodentium Andrea Portt, McGill University, Montreal October 9th, 2010 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Master’s in Microbiology © Andrea Portt 2010 Table of Contents LIST OF ABBREVIATIONS 3 ABSTRACT 6 ACKNOWLEDGEMENTS 7 CONTRIBUTIONS OF AUTHORS 8 LITERATURE REVIEW 9 2. OMPTINS 9 3. OMPTIN SUBSTRATES 13 A. ANTIMICROBIAL PEPTIDES 13 B. BLOOD CLOTTING PROTEINS AND EXTRACELLULAR MATRIX 14 C. COMPLEMENT 16 D. TROPOMYOSIN 17 4. EVOLUTION OF OMPTINS 17 5. OMPTIN REGULATION 20 6. OMPTINS OF PATHOGENIC ENTEROBACTEREACEAE 22 A. Y. PESTIS 22 B. S. ENTERICA 23 C. SHIGELLA 25 D. ATTACHING AND EFFACING BACTERIA 25 INTRODUCTION 28 MATERIALS AND METHODS 29 1. BACTERIAL GROWTH 29 2. BACTERIAL STRAINS AND CONSTRUCTION OF PLASMIDS 29 A. STRAINS 29 B. PLASMIDS 31 3. DISK INHIBITION ASSAYS 34 4. MINIMUM INHIBITORY CONCENTRATION DETERMINATIONS 34 5. PROTEOLYTIC CLEAVAGE OF AMPS BY CELLS EXPRESSING OMPTINS 34 6. OM DISRUPTION ASSAY WITH 1-N-PHENYLNAPHTHYLAMINE 35 7. DEGRADATION OF TROPOMYOSIN BY E. COLI AND C. RODENTIUM STRAINS EXPRESSING OMPTINS 35 8. REAL-TIME QUANTITATIVE PCR 35 9. PURIFICATION OF NATIVE CROP 35 10. EXPRESSION, PURIFICATION, AND REFOLDING OF HIS-PGTE AND HIS-CROP 36 A. EXPRESSION 36 B. PURIFICATION 36 C. REFOLDING 36 11. CLEAVAGE OF C2 FRET SUBSTRATE BY WHOLE CELLS OR PURIFIED OMPTINS 37 A. WHOLE CELLS 37 B. PURIFIED OMPTINS 37 1 RESULTS 38 1. GROWTH INHIBITION OF E. COLI AND C. RODENTIUM STRAINS EXPRESSING OMPTINS BY C18G.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • B1–Proteases As Molecular Targets of Drug Development
    Abstracts B1–Proteases as Molecular Targets of Drug Development B1-001 lin release from the beta cells. Furthermore, GLP-1 also stimu- DPP-IV structure and inhibitor design lates beta cell growth and insulin biosynthesis, inhibits glucagon H. B. Rasmussen1, S. Branner1, N. Wagtmann3, J. R. Bjelke1 and secretion, reduces free fatty acids and delays gastric emptying. A. B. Kanstrup2 GLP-1 has therefore been suggested as a potentially new treat- 1Protein Engineering, Novo Nordisk A/S, Bagsvaerd, Denmark, ment for type 2 diabetes. However, GLP-1 is very rapidly degra- 2Medicinal Chemistry, Novo Nordisk A/S, Maaloev, Denmark, ded in the bloodstream by the enzyme dipeptidyl peptidase IV 3Discovery Biology, Novo Nordisk A/S, Maaloev, DENMARK. (DPP-IV; EC 3.4.14.5). A very promising approach to harvest E-mail: [email protected] the beneficial effect of GLP-1 in the treatment of diabetes is to inhibit the DPP-IV enzyme, thereby enhancing the levels of The incretin hormones GLP-1 and GIP are released from the gut endogenously intact circulating GLP-1. The three dimensional during meals, and serve as enhancers of glucose stimulated insu- structure of human DPP-IV in complex with various inhibitors 138 Abstracts creates a better understanding of the specificity and selectivity of drug-like transition-state inhibitors but can be utilized for the this enzyme and allows for further exploration and design of new design of non-transition-state inhibitors that compete for sub- therapeutic inhibitors. The majority of the currently known DPP- strate binding. Besides carrying out proteolytic activity, the IV inhibitors consist of an alpha amino acid pyrrolidine core, to ectodomain of memapsin 2 also interacts with APP leading to which substituents have been added to optimize affinity, potency, the endocytosis of both proteins into the endosomes where APP enzyme selectivity, oral bioavailability, and duration of action.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Proquest Dissertations
    urn u Ottawa L'Universitd canadienne Canada's university FACULTE DES ETUDES SUPERIEURES l^^l FACULTY OF GRADUATE AND ET POSTDOCTORALES u Ottawa POSTDOCTORAL STUDIES I.'University emiadienne Canada's university Charles Gyamera-Acheampong AUTEUR DE LA THESE / AUTHOR OF THESIS Ph.D. (Biochemistry) GRADE/DEGREE Biochemistry, Microbiology and Immunology FACULTE, ECOLE, DEPARTEMENT / FACULTY, SCHOOL, DEPARTMENT The Physiology and Biochemistry of the Fertility Enzyme Proprotein Convertase Subtilisin/Kexin Type 4 TITRE DE LA THESE / TITLE OF THESIS M. Mbikay TIRECTWRTDIRICTR^ CO-DIRECTEUR (CO-DIRECTRICE) DE LA THESE / THESIS CO-SUPERVISOR EXAMINATEURS (EXAMINATRICES) DE LA THESE/THESIS EXAMINERS A. Basak G. Cooke F .Kan V. Mezl Gary W. Slater Le Doyen de la Faculte des etudes superieures et postdoctorales / Dean of the Faculty of Graduate and Postdoctoral Studies Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 Ottawa ON K1A 0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-59504-6 Our file Notre reference ISBN: 978-0-494-59504-6 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats.
    [Show full text]
  • Proteolytic Enzymes in Grass Pollen and Their Relationship to Allergenic Proteins
    Proteolytic Enzymes in Grass Pollen and their Relationship to Allergenic Proteins By Rohit G. Saldanha A thesis submitted in fulfilment of the requirements for the degree of Masters by Research Faculty of Medicine The University of New South Wales March 2005 TABLE OF CONTENTS TABLE OF CONTENTS 1 LIST OF FIGURES 6 LIST OF TABLES 8 LIST OF TABLES 8 ABBREVIATIONS 8 ACKNOWLEDGEMENTS 11 PUBLISHED WORK FROM THIS THESIS 12 ABSTRACT 13 1. ASTHMA AND SENSITISATION IN ALLERGIC DISEASES 14 1.1 Defining Asthma and its Clinical Presentation 14 1.2 Inflammatory Responses in Asthma 15 1.2.1 The Early Phase Response 15 1.2.2 The Late Phase Reaction 16 1.3 Effects of Airway Inflammation 16 1.3.1 Respiratory Epithelium 16 1.3.2 Airway Remodelling 17 1.4 Classification of Asthma 18 1.4.1 Extrinsic Asthma 19 1.4.2 Intrinsic Asthma 19 1.5 Prevalence of Asthma 20 1.6 Immunological Sensitisation 22 1.7 Antigen Presentation and development of T cell Responses. 22 1.8 Factors Influencing T cell Activation Responses 25 1.8.1 Co-Stimulatory Interactions 25 1.8.2 Cognate Cellular Interactions 26 1.8.3 Soluble Pro-inflammatory Factors 26 1.9 Intracellular Signalling Mechanisms Regulating T cell Differentiation 30 2 POLLEN ALLERGENS AND THEIR RELATIONSHIP TO PROTEOLYTIC ENZYMES 33 1 2.1 The Role of Pollen Allergens in Asthma 33 2.2 Environmental Factors influencing Pollen Exposure 33 2.3 Classification of Pollen Sources 35 2.3.1 Taxonomy of Pollen Sources 35 2.3.2 Cross-Reactivity between different Pollen Allergens 40 2.4 Classification of Pollen Allergens 41 2.4.1
    [Show full text]
  • Structure Prediction of Outer Membrane Protease Protein of Salmonella Typhimurium Using Computational Techniques
    INT. J. BIOAUTOMATION, 2016, 20(1), 5-18 Structure Prediction of Outer Membrane Protease Protein of Salmonella typhimurium Using Computational Techniques Rozina Tabassum*, Muhammad Haseeb, Sahar Fazal Department of Bioinformatics and Biosciences Mohammad Ali Jinnah University Islamabad, Pakistan E-mails: [email protected], [email protected], [email protected] *Corresponding author Received: April 04, 2015 Accepted: November 16, 2015 Published: March 31, 2016 Abstract: Salmonella typhimurium, a facultative gram-negative intracellular pathogen belonging to family Enterobacteriaceae, is the most frequent cause of human gastroenteritis worldwide. PgtE gene product,outer membrane protease emerges important in the intracellular phases of salmonellosis. The pgtE gene product of S. typhimurium was predicted to be capable of proteolyzing T7 RNA polymerase and localize in the outer membrane of these gram negative bacteria. PgtE product of S. enterica and OmpT of E. coli, having high sequence similarity have been revealed to degrade macrophages, causing salmonellosis and other diseases. The three-dimensional structure of the protein was not available through Protein Data Bank (PDB) creating lack of structural information about E protein. In our study, by performing Comparative model building, the three dimensional structure of outer membrane protease protein was generated using the backbone of the crystal structure of Pla of Yersinia pestis, retrieved from PDB, with MODELLER (9v8). Quality of the model was assessed by validation tool PROCHECK, web servers like ERRAT and ProSA are used to certify the reliability of the predicted model. This information might offer clues for better understanding of E protein and consequently for developmet of better therapeutic treatment against pathogenic role of this protein in salmonellosis and other diseases.
    [Show full text]
  • Final Program
    In Memoriam: Final Program XXV Congress of the International Society on Thrombosis and Haemostasis and 61st Annual SSC Meeting June 20 – 25, 2015 Toronto, Canada www.isth2015.org 1 Final Program Table of Contents 3 Venue and Contacts 5 Invitation and Welcome Message 12 ISTH 2015 Committees 24 Congress Support 25 Sponsors and Exhibitors 27 ISTH Awards 32 ISTH Society Information 37 Program Overview 41 Program Day by Day 55 SSC and Educational Program 83 Master Classes and Career Mentorship Sessions 87 Nurses Forum 93 Scientific Program, Monday, June 22 94 Oral Communications 1 102 Plenary Lecture 103 State of the Art Lectures 105 Oral Communications 2 112 Abstract Symposia 120 Poster Session 189 Scientific Program, Tuesday, June 23 190 Oral Communications 3 198 Plenary Lecture 198 State of the Art Lectures 200 Oral Communications 4 208 Plenary Lecture 209 Abstract Symposia 216 Poster Session 285 Scientific Program, Wednesday, June 24 286 Oral Communications 5 294 Plenary Lecture 294 State of the Art Lectures 296 Oral Communications 6 304 Abstract Symposia 311 Poster Session 381 Scientific Program, Thursday, June 25 382 Oral Communications 7 390 Plenary Lecture 390 Abstract Symposia 397 Highlights of ISTH 399 Exhibition Floor Plan 402 Exhibitor List 405 Congress Information 406 Venue Plan 407 Congress Information 417 Social Program 418 Toronto & Canada Information 421 Transportation in Toronto 423 Future ISTH Meetings and Congresses 2 427 Authors Index 1 Thank You to Everyone Who Supported the Venue and Contacts 2014 World Thrombosis Day
    [Show full text]
  • Loss of Protease Activity of ADAM15 Abolishes Protective Effects on Plaque Progression in Atherosclerosis
    382 Letters to the Editor Loss of protease activity of ADAM15 abolishes protective effects on plaque progression in atherosclerosis Andreas Bültmann, Zhongmin Li, Silvia Wagner, Meinrad Gawaz, Martin Ungerer, Harald Langer, Andreas E. May ⁎⁎, Götz Münch ⁎ Corimmun, Fraunhofer Str. 17, D-82152 Martinsried, Germany Medizinische Klinik III, Eberhard-Karls Universität Tübingen, D-72076 Tübingen, Germany article info For the induction of atherosclerosis, rabbits were fed with Western Article history: type high cholesterol (0.25%) diet for 8 weeks and vascular gene Received 8 August 2011 transfer to the carotid artery was performed as previously described Accepted 13 August 2011 [7]. Available online 9 September 2011 Animals were sacrificed 4 weeks after the adenovirus delivery. Keywords: The left common carotid arteries, aorta and iliac arteries were Atherosclerosis macroscopically prepared for “en face” evaluation of plaque ADAM15 extension and stained with Sudan III. Serial 6-μm-thick cryosections Sheddase were cut and histological assessment of atherosclerosis after Metalloproteinase hematoxylin eosin (HE) and van Gieson (VG)-elastica staining and GFP expression were performed. Immunohistochemical analysis, with anti rabbit RAM 11 antibody (DAKO, Hamburg, Germany) was The A Disintegrin And Metallporteinases (ADAMs) contain a used for macrophages as previously described [12]. metalloprotease-like and a disintegrin-like domain. Currently 40 After vascular gene transfer into the carotid artery, GFP expression different types of ADAM proteins have been identified. ADAM15 is could be detected with AdGFP and also with Ad-ADAM15 and Ad- found in the myocardium [1,2], endothelial cells and in vascular ADAM15 prot neg, which both co-expressed GFP (Fig. 1). Relative atherosclerotic lesions [3].
    [Show full text]
  • International Journal of Advanced and Applied Sciences, 4(12) 2017, Pages: 31-35
    International Journal of Advanced and Applied Sciences, 4(12) 2017, Pages: 31-35 Contents lists available at Science-Gate International Journal of Advanced and Applied Sciences Journal homepage: http://www.science-gate.com/IJAAS.html Tertiary structure prediction of bromelain from Ananas Comosus using comparative modelling method Fatahiya Mohamed Tap 1, Fadzilah Adibah Abd Majid 2, *, Nurul Bahiyah Ahmad Khairudin 1 1Chemical Energy Conversion and Applications Group, Malaysia Japan International Institute of Technology, Universiti Teknologi Malaysia, Kuala Lumpur, Malaysia 2Institute of Marine Biotechnology, Universiti Malaysia Terengganu, 21030 Kuala Terengganu, Malaysia ARTICLE INFO ABSTRACT Article history: Bromelain is a general name for a family of sulfhydryl which can be found in Received 21 February 2017 the proteolytic enzyme group from pineapples (Ananas Comosus). This study Received in revised form focuses on the prediction of three dimensional structures (3D) of stem 2 October 2017 bromelain using the method of comparative modelling. The amino acid Accepted 8 October 2017 sequence of bromelain was obtained from the NCBI database was used as a tool to search for proteins with known 3D structures related to the target Keywords: sequence. Suitable template was chosen based on >30% sequence similarity Bromelain and lowest e-value. Based on these criteria, 1YAL was selected as the best Comparative modelling template with 55% of sequence similarity and 9x10-52 of e-value. Sequence alignment © 2017 The Authors. Published by IASE. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1. Introduction industrial and pharmacology area, therefore it is essential to maintain and improve bromelain *Bromelain can be derived from stem and fruit of properties in conformation and catalytic activity in pineapples.
    [Show full text]
  • Concentrate of Proteolytic Enzymes Enriched in Bromelain
    20 September 2012 EMA/648483/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report NexoBrid Concentrate of proteolytic enzymes enriched in bromelain Procedure No. EMEA/H/C/002246 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 5 1.1. Submission of the dossier.................................................................................... 5 1.2. Steps taken for the assessment of the product ....................................................... 6 2. Scientific discussion ................................................................................ 7 2.1. Introduction ...................................................................................................... 7 2.2. Quality aspects .................................................................................................. 9 2.3. Non-clinical aspects .......................................................................................... 20 2.4. Clinical aspects ................................................................................................ 29 2.5.
    [Show full text]
  • Schneider-Dissertation-2019
    Biosynthetic Investigation, Synthesis, and Bioactivity Evaluation of Putative Peptide Aldehyde Natural Products From the Human Gut Microbiota The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Schneider, Benjamin Aaron. 2019. Biosynthetic Investigation, Synthesis, and Bioactivity Evaluation of Putative Peptide Aldehyde Natural Products From the Human Gut Microbiota. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:42029686 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use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
    [Show full text]